Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT

Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT

Abstract Background Gastro-intestinal stromal tumors (GISTs) are very rare tumors of the gastro-intestinal tract, originating from the interstitial cells of Cajal or a common cell precursor which both express type III tyrosine kinase receptors. Regorafenib is an oral multi-kinase inhibitor used to t...

Full description

Bibliographic Details
Main Authors: Donatienne Van Weehaeghe, Olivier Gheysens, Vincent Vandecaveye, Patrick Schöffski, Koen Van Laere, Christophe M. Deroose
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Subjects:
GIST
18F–FDG-PET/CT
Regorafenib
Follow-up
Attenuation-artefact
Respiratory motion
Online Access:http://link.springer.com/article/10.1186/s12885-018-4154-7

Internet

http://link.springer.com/article/10.1186/s12885-018-4154-7

Similar Items